Sana Biotechnology (NASDAQ:SANA) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Sana Biotechnology (NASDAQ:SANA) from a hold rating to a sell rating in a report issued on Monday morning.

A number of other research firms also recently weighed in on SANA. Weiss Ratings downgraded shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Wedbush raised their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Finally, Rodman & Renshaw began coverage on Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.50.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.14 on Monday. Sana Biotechnology has a 52 week low of $2.61 and a 52 week high of $6.55. The stock’s 50 day moving average price is $3.26 and its two-hundred day moving average price is $3.60. The stock has a market capitalization of $873.83 million, a price-to-earnings ratio of -3.38 and a beta of 2.13.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. On average, equities research analysts forecast that Sana Biotechnology will post -0.59 EPS for the current year.

Institutional Trading of Sana Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of SANA. Vanguard Group Inc. increased its holdings in shares of Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares during the last quarter. State Street Corp raised its position in shares of Sana Biotechnology by 20.6% in the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after purchasing an additional 1,374,300 shares during the period. Geode Capital Management LLC raised its position in shares of Sana Biotechnology by 20.3% in the fourth quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock valued at $16,763,000 after purchasing an additional 694,606 shares during the period. Integral Health Asset Management LLC boosted its holdings in shares of Sana Biotechnology by 50.0% during the 4th quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock worth $12,210,000 after buying an additional 1,000,000 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Sana Biotechnology by 148.4% during the 1st quarter. Bank of America Corp DE now owns 2,946,861 shares of the company’s stock worth $8,487,000 after buying an additional 1,760,610 shares during the period. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.